Creating effective therapies for patients with advanced cancer

Mission and impact

Ernest Pharmaceuticals’ mission is to create effective therapies for advanced stage solid tumor patients. The first focus is on cancers with low survival rates, such as advanced liver, pancreatic and ovarian cancer. For these patients, few therapeutic options exist that greatly improve overall survival time. Bacterial cancer therapies have the potential to change these high mortality rates and make a significant impact on the lives of patients that have exhausted all treatment options.

Advanced disease

More than 50% of patients with liver, pancreatic and ovarian tumors get diagnosed at a later stage, once the disease has already spread. Yearly 70,000 patients in the United States get diagnosed at this stage, for which currently no curative treatments exist. The combined 5-year survival of this group is 11%.

Ernest Pharmaceuticals’ therapies are designed to overcome the specific obstacles that prevent effective treatment of these tumor types, such as tumor heterogeneity and tumor spread and can treat the patient’s full tumor burden.